Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561487 | 1.00 | TTR (0.57) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL4427604 | 0.86 | TTR (0.69) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL4427602 | 0.86 | TTR (0.69) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL29445626 | 0.84 | TTR (0.54) | TTRCA12CA1CA2CA7 | |
| SCHEMBL2213002 | 0.84 | TTR (0.54) | TTRCA12CA1CA2CA7 | |
| SCHEMBL2213006 | 0.84 | TTR (0.54) | TTRCA12CA1CA2CA7 | |
| SCHEMBL767759 | 0.83 | CA12 (0.71) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL767758 | 0.83 | CA12 (0.71) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL24876 | 0.82 | MEN1 (0.65) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL24877 | 0.82 | MEN1 (0.65) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105976-B | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022042666-A1 | SELECTIVE ROCK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2022-03-03 | — | — | WO | disclosed |
| CN-114105976-A | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-105579438-B | Compounds and methods for skin repair | 阿勒根公司 | 2019-12-06 | — | — | CN | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-9546162-B2 | Compounds and methods for skin repair | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-3049392-A1 | COMPOUNDS AND METHODS FOR SKIN REPAIR | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015048553-A1 | COMPOUNDS AND METHODS FOR SKIN REPAIR | ALLERGAN, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150094330-A1 | COMPOUNDS AND METHODS FOR SKIN REPAIR | ALLERGAN INC (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TTR 2118/4885DPP4 994/4885CA12 1716/4885 |
| US-20150094330-A1 | COMPOUNDS AND METHODS FOR SKIN REPAIR | PTGER4, LTB4R2, LTB4R | TTR 4777/4885DPP4 457/4885CA12 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.